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Enzymically-deglycosylated antibody IgE lost-its allergic activity in mouse systemic anaphylaxis,
though the IgE kept its antibody activity. IgEantibody obtainedfrom mice treated with a substance
extractedfrom human urine was deglycosylated. This IgE also lost the allergic activity on the sys-
temic anaphylaxis but kept its antibody activity. Thesefindings strongly suggest that glycosylation
ofIgE has a close relation to the binding ofthe Fc receptor, and that humans have another anti-
allergic mechanism: in vivo IgE antibody deglycosylation induced by the substance.
INTRODUCTION
A substance extracted from human
urine with a urea precipitation method has
been shown to have anti-allergic activity in
both human and mouse and is used for
treatment of allergic diseases in Japan.
This substance does not affect the produc-
tion of antibody IgE, and the anti-allergic
activity is not found immediately after the
treatment [1]. This substance has been rec-
ognized as a polypeptide with the molecu-
lar weight of 1 K Da, but, in spite ofmany
previous efforts, the amino acid sequence
has not been currently clarified.
In allergic reactions, IgE antibody
binds to the receptors ofmastcells, andthe
mast cells secrete chemotactic factors
which induce allergic symptoms. Granato
and Neeser have reported that enzymical-
ly-deglycosylated IgE retains antigen-
binding activity but loses its ability to bind
to the mast cell receptors [2].
Here we hypothesize that the urine-
derived substance decreases glycosylation
of IgE antibody, and this deglycosylation
decreases the allergic reactions of both of
human and mouse. In this paper we report
effects of the enzymically-deglycosylated
mouse IgE antibody on the allergic reac-
tions and investigate the effects of the
urine-derived substance on IgE antibody
deglycosylation.
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MATERIALS AND METHODS
Animals
Male ddY mice (SLC Co., Tokyo,
Japan), 8 weeks old, were used. They were
housed in groups of five in plastic cages
(338 x 140 x 225 mm) with free access to
food (F2: Funabashi Co., Tokyo, Japan)
and water. The animal room was kept at 21
to 25°C with 50 to 60 percent humidity
and illumination from 7:00 to 19:00. The
following experiments were performed
from 15:00 to 17:00. All of the experi-
ments were approved by the Ethics Com-
mittee for Animal Experiments of Akita
University School ofMedicine, Japan.
Animalpreparations
Animal preparations were performed
as previously reported [1] with some mod-
ifications. Briefly, 200 mice were
intraperitoneally injected with 10 mg/kg
of ovalbumin (OA; Sigma Co., St. Louis,
MA, USA) prepared with physiological
saline (pS)b. Seven days after the injec-
tion, 80 mice were immunized intraperi-
toneally by injection of 3 mg/kg of OA;
another 40 mice with 3 mg/kg of OA and
1 mg/kg of the substance (obtained from
Nihon Kayaku Co., Tokyo, Japan) pre-
pared with PS; another 40 mice with 3
mg/kg of OA and 10 mg/kg of the sub-
stance; and the other40 mice with 3 mg/kg
of OA and 100 mg/kg of the substance.
Three days after the second injections,
serum was individually collected from
these mice.
Purification of the antibody IgE
The anti-OA IgE was purified from
the serum using an affinity column bound
with OA and an affinity column bound
with anti-mouse IgE rat IgG (Southern
Biotechnology, Inc., Birmingham, AL,
USA). Furthermore, to exclude contami-
nation with IgG, the IgE was further puri-
fied using an affinity column bound with
anti-mouse IgG sheep IgG (Rockland,
Gilbertsville, PA, USA). The purity of the
IgE was confirmed with the use of SDS-
PAGE.
Enzymic-deglycosylation of the
antibody IgE
Ten mg of the purified anti-OA IgE
obtained from mice treated with only OA
was prepared with citrate-acetate buffer
pH 4.0 and incubated at 37°C for 24 hours
with 10 mU ofGlycopeptidase A (EC 3, 5,
1, 52; Seikagaku Co., Tokyo, Japan). The
solution was desalted, and the anti-OA IgE
was purified using the affinity column
bound with anti-mouse IgE rat IgG.
Glycosylation ofthe anti-OA IgE
Antibody IgEs purified as above and
the enzymically-treated antibody IgE were
prepared at 1 mg/ml with PS. One hundred
p1 ofeach ofthe IgE solutions was poured
into wells of a 96-well plastic plate (Sum-
itomo Bakelite Co., Tokyo, Japan). After
two hours at room temperature (RT). the
wells were washed three times with wash-
ing solution (WS: PS containing 1 mM
tris-HCl pH 7.4 and 0.005 percent Tween
20 from Wako Co., Osaka, Japan). As a
blocking solution, 330 p1 of 5 percent
bovine serum albumin (Sigma) was
poured into the wells and was left for 30
minutes at RT. Then, the wells were
washed three times with WS. Then 100 p1
of biotinized lectins prepared at 2 pg/ml
with PS was poured into the wells. Each of
the biotinized lectins used in the present
study specifically recognizes the terminal
structure of IgE sugar chains (DSA;
Galpl-4GlcNAc, AAL; Fucal-2Gal or
SSA; Siala2-6Gal, Hohnen Co., Tokyo,
Japan). After incubation for one hour at
RT, the wells were washed four times with
WS and then 100 p1 ofhorseradish perox-
idase-avidin (Hohnen) prepared at 0.1
pg/ml with PS was poured into the wells.
After incubation for 30 minutes at RT, the
wells was washed five times with WS.
Color was developed with the use of the
coloring kit (Sumitomo Bakelite). The
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was measured at the dual wavelengths of
450 and 655 nm. These procedures were
performed following the lectin-ELISA
method previously described [3].
Antibody activities of the IgEs
One hundred l of each of the IgE
solutions prepared as above was poured
into a well previously coated with 10 per-
cent OA in a 96-well plastic plate (Sumit-
omo Bakelite). After two hours incubation
at RT, the wells were washed three times
with WS as described above. One hundred
,ul of horseradish-peroxidase conjugated
anti-mouse IgE rat IgG (Southern Biotech-
nology) prepared to 2 ,ug/ml with PS was
poured into the wells. After incubation for
one hour at RT, the wells were washed
four times with WS, and color was devel-
oped with the use of the coloring kit. The
light absorbance of the colored product
was measured at the dual wavelengths of
450 and 655 nm.
Activity ofthe antibody IgE on
mouse systemic anaphylaxis
Antibody IgE-inducing systemic ana-
phylaxis experiments were previously
reported [4]. The detection of the allergic
activities ofthe IgEs was performed as fol-
lows. Briefly, the anti-OA IgE of the mice
treated with OA only, that of the mice
treated also with 100 mg/kg of the sub-
stance and the enzymically-deglycosylat-
ed anti-OA IgE were individually injected
intraperitoneally into 10 intact mice at the
dose of 0.7 mg/kg; as a control, 100 p1 of
PS was injected to the another 10 intact
mice. One hour after these injections, the
thickness ofthe right rear footpad ofthese
mice was individually measured. Twenty-
three hours after this, these mice were
injected with 1 mg/kg of OA in 100 VI of
PS containing 0.5 percent Evans Blue Dye
(Sigma) through their tail vein. Twenty-
five minutes after the injection, the body
temperature was measured using a rectal
thermometer (Terumo Co., Tokyo, Japan)
for two minutes. One hour after the injec-
tion, the thickness ofthe right rear footpad
was also measured, and at the same time,
the leakage ofthe dye was observed in the
ear skin.
RESULTS
Table 1 indicates the deglycosylations
ofthe anti-OA IgEs. Thereactivities ofthe
terminal sugar chain structures of the
enzymically-treated IgE were not found
(Table 1, upper). Those of IgEs obtained
from the mice treated with the substance
were decreased in a dose-dependent way
(Table 1, lower).
The enzymatic removal of sugar
chains did not affect thebinding activity to
OA of the IgE antibody (Table 2, upper).
Furthermore, the IgE deglycosylated by
the urine-derived substance also showed
comparable antibody activity (Table 2,
lower).
The mice treated with the anti-OA IgE
with intact sugar chains (collected from
mice treated with OA only) showed the
distinctive systemic anaphylaxis, which
was indicated by decrease of the body
temperature, swelling of the footpad and
dye leakage in the ear skin. The mice treat-
ed with the anti-OA IgE lacking the sugar
chains (collected from mice treated with
100 mg/kg of the substance) or the
enzymically-deglycosylated IgE did not
show the symptoms of systemic anaphy-
laxis, nor did the control mice (Table 3).
DISCUSSION
The sugar chain structures of IgE are
in the Fc portion of the molecule, the por-
tion that binds to the Fc receptor of cells
mediating allergic reactions. Granato and
Neeser have already reported that IgE-gly-
cosylation relates to the receptor-binding
but not to the antibody activity [2]. The
present findings clearly indicate that the
glycosylation of antibody IgE has a close
relation to the activity inducing allergic
reactions, which strongly suggest that the148 Masuda et al.: Anti-allergic mechanism of the substance
Table 1. Reactivities of terminal sugar chain structures in anti-OA IgE.
Light absorbance at 450 and 655 nm
Terminal sugar chain structure
Anti-OA IgE Galpl-4Glc Fucai-3Gal Siala2-6Gal
Intact 0.108 0.073 0.068
Enzymically-treated 0.019 0.007 0.007
Anti-OA IgE obtained from mice
treated with the substance
1 mg/kg 0.084 0.058 0.058
10 mg/kg 0.078 0.052 0.052
100 mg/kg 0.028 0.008 0.006
Blank control: 0.003 0.003 0.001
5% BSA
Values in this table indicate the reactivity of 1 mg/ml of the IgE solutions.
OA, ovalbumin; BSA, bovine serum albumin.
Table 2. Antibody activities of the anti-OA IgEs.
Light absorbance at 450 and 655 nm
Anti-OA IgE Anti-OA reactivity
With sugar chains, intact 0.144
No sugar chain, enzymically-treated 0.148
Anti-OA IgE obtained from mice
treated with the substance
1 mg/kg 0.151
10 mg/kg 0.150
100 mg/kg 0.152
Blank control: 0.001
10% OA
Values in this table indicate the reactivity of 1 mg/ml of the IgE solutions.
OA, ovalbumin.
sugar chain structures modify the biologi-
cal activities of the IgE. Since treatment
with the glycopeptidase does not change
the amino acid sequence of the IgE, the
sugar chain structures may affect the
hyper-structure of the Fc portion of the
IgE. But, the mechanism of the effect on
the Fc receptor binding is not yet clear.
Allergic reactions are important in
recognizing harmful circumstances, but
excessive allergic responses can lead to
injury. Not only mouse but also humans
regulate and block some aspects of the
excessive immune responses. In the pre-
sent studies, the IgE antibody obtained
from mice treated with a substance
extracted from human urine decreased the
allergic activity ofIgE antibody via degly-
cosylation. This appears to be an example
of one of the blocking systems.Masuda etal.: Anti-allergic mechanism of the substance 149
Table 3. Systemic anaphylaxis induced by the anti-OA IgE.
Anaphylaxis symptoms
Rectal Swelling of Number of
temperature the footpad mice showing
Anti-OA IgE (QC) (mm) dye leakage
With sugar chains, intact 35.8 + 0.32* 0.50 + 0.10* 10
No sugar chain, 39.2 + 0.19 0.02 + 0.03 0
enzymically treated
Anti-OA IgE obtained from mice
treated with the substance
100 mg/kg 39.1 + 0.20 0.02 + 0.02 0
Control: 38.9 + 0.22 0.02 + 0.01 0
IgE obtained from
the mice not immunized
with OA
Values in this table indicates the mean + SE of the rectal temperatures and the swelling of
the footpad (the differences of the second measured and the first measured) in the 10
mice.
*p < 0.01 compared to the control (Mann-Whitney U test).
OA, ovalbumin; PS, physiological saline.
The amino acid sequence of the sub-
stance is an important aspect of the char-
acterization of the urine-derived sub-
stance. We tried to determine the amino
acid sequence of this substance using a
protein sequencer, but the substance did
not attach to the detecting membrane. This
observation strongly suggests that the sub-
stance may have a very hydrophilic struc-
ture, perhaps resulting from the presence
of sugar chains. The previous report indi-
cated that the amino acids composing the
substance are serine, threonine and
asparagine [1]. These amino acids are
potential sites of linkage of sugar chains.
We speculate that the humoral anti-allergic
polypeptide, the precursor of the urine-
derived substance, is glycosylated and
excreted in urine. Regretfully, the amino
acid sequence of the precursor has not
been clarified at the present time.
The present findings suggest another
aspect of human allergic reactions. Inten-
sity ofallergic reaction differs among indi-
vidual patients. Part ofthis difference may
be based on IgE antibody glycosylation.
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